To study the long-term efficacy and safety of 4-aminopyridine in patients with multiple sclerosis.
Case series, follow-up varying from 6 to 32 months.
University referral center.
Thirty-one patients with definite MS, 23 of them being exposed to long-term administration (6 to 32 months) of 4-aminopyridine, since they showed a favorable initial response to the drug.
Long-term oral treatment with 4-aminopyridine in daily doses of up to 0.5 mg/kg of body weight.
Main Outcome Measures:
Neurologic functions and symptoms as reported by the patients; side effects.
Twenty of 23 patients who showed a favorable initial response benefited from long-term administration. Ambulation and fatigue (each in 13 patients) and visual function (in five patients) were most frequently reported to be improved. Three major side effects did occur during a follow-up of 406 patient months: a generalized epileptic seizure in two patients and hepatitis in one.
Although a substantial proportion of patients with multiple sclerosis seem to benefit from long-term administration of 4-aminopyridine, additional studies are needed to clarify the exact value of the drug.
Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety. Arch Neurol. 1994;51(3):292–296. doi:10.1001/archneur.1994.00540150090022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: